Back to Search Start Over

The evolving value assessment of cancer therapies: Results from a modified Delphi study

Authors :
Myrto Lee
Hugo Larose
Martin Gräbeldinger
Jon Williams
Anne-Marie Baird
Susan Brown
Johannes Bruns
Russell Clark
Javier Cortes
Giuseppe Curigliano
Andrea Ferris
Louis P. Garrison
Y.K. Gupta
Ravindran Kanesvaran
Gary Lyman
Luca Pani
Zack Pemberton-Whiteley
Tomas Salmonson
Peter Sawicki
Barry Stein
Dong-Churl Suh
Galina Velikova
Jens Grueger
Source :
Health Policy Open, Vol 6, Iss , Pp 100116- (2024)
Publication Year :
2024
Publisher :
Elsevier, 2024.

Abstract

The move toward early detection and treatment of cancer presents challenges for value assessment using traditional endpoints. Current cancer management rarely considers the full economic and societal benefits of therapies. Our study used a modified Delphi process to develop principles for defining and assessing value of cancer therapies that aligns with the current trajectory of oncology research and reflects broader notions of value. 24 experts participated in consensus-building activities across 5 months (16 took part in structured interactions, including a survey, plenary sessions, interviews, and off-line discussions, while 8 participated in interviews). Discussion focused on: 1) which oncology-relevant endpoints should be used for assessing treatments for early-stage cancer and access decisions for early-stage treatments, and 2) the importance of additional value components and how these can be integrated in value assessments. The expert group reached consensus on 4 principles in relation to the first area (consider oncology-relevant endpoints other than overall survival; build evidence for endpoints that provide earlier indication of efficacy; develop evidence for the next generation of predictive measures; use managed entry agreements supported by ongoing evidence collection to address decision-maker evidence needs) and 3 principles in relation to the second (routinely use patient reported outcomes in value assessments; assess broad economic impact of new medicines; consider other value aspects of relevance to patients and society).

Details

Language :
English
ISSN :
25902296
Volume :
6
Issue :
100116-
Database :
Directory of Open Access Journals
Journal :
Health Policy Open
Publication Type :
Academic Journal
Accession number :
edsdoj.4d6e9cf3a8d4b7d88dee937863945b9
Document Type :
article
Full Text :
https://doi.org/10.1016/j.hpopen.2024.100116